Monte Rosa Therapeutics, Inc.

Contributing Author

Recent Articles by Monte Rosa Therapeutics, Inc.

Oct-24	Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases GLUE GlobeNewswire
Sep-15	Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases GLUE GlobeNewswire
Sep-02	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences GLUE GlobeNewswire
Aug-07	Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates GLUE GlobeNewswire
Jul-21	Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases GLUE GlobeNewswire
Jul-03	Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines GLUE GlobeNewswire
Jun-10	Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases GLUE GlobeNewswire
May-28	Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference GLUE GlobeNewswire
May-08	Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates GLUE GlobeNewswire